Citations

Clear

1575 citation(s) found for "Im, Gene".

Complex regulation of class II gene expression: analysis with class II mutant cell lines.
Glimcher, L H, McKean, D J, Choi, Eunna , Seidman, J G, Seidman, Jonathan G. , Seidman, Jonathan G , Choi, E

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 135 | Issue: 5 | Pages: 3542-3550

10.4049/jimmunol.135.5.3542 Get It

Abstract Several Ia-negative variants of a homozygous Iad-expressing antigen-presenting B lymphoma cell line, M12, have been obtained by repeated cycles of negative immunoselection after mutagenesis with ethylmethane sulfonate or gamma-irradiation. Two such Iad-negative cell lines, selected with a mixture of alpha I-Ad and alpha I-Ed monoclonal antibodies, failed to present antigen to all cloned Iad-restricted T cells tested, whereas the third cell line, selected with alpha I-Ad reagents only, stimulated I-Ed but not I-Ad-restricted T cells. The mutations in all three cell lines resulted in the absence of RNA specific for the A beta d gene. In addition, two-dimensional gel electrophoresis of immunoprecipitates from one of the I-Ed-negative cell lines demonstrated the presence of intracytoplasmic Ed polypeptides that exhibited significantly decreased amounts of oligosaccharide-induced heterogeneity. The introduction of class II A beta b and A alpha b genes by DNA-mediated transfection resulted in the serologic and functional expression of a class II I-Ab molecule but not the reexpression of the endogenous class II molecules; thus a transacting regulatory element is unlikely to be the target of the mutagenic event. The analysis of these and other Ia variant cell lines may prove useful in understanding the molecular mechanisms that control the expression of class II molecules in B cells.
Immune response gene products (Ia antigens) on glial and endothelial cells in virus-induced demyelination.
Pierce, Mabel L., Howie, E A, Rodriguez, Moses

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 138 | Issue: 10 | Pages: 3438-3442

10.4049/jimmunol.138.10.3438 Get It

Abstract Theiler's murine encephalomyelitis virus induced central nervous system demyelination in susceptible strains of mice with s, q, v, p, and f H-2D alleles. We used immunoelectron microscopy to look for differential production of class II immune response gene products (Ia) within astrocytes, oligodendrocytes, microglia, and endothelial cells. Spinal cord sections from susceptible mice (B10.S and B10.ASR2) showed increased content of Ia in glial and endothelial cells. In contrast, resistant mice [B10.S(9R)] showed minimal Ia production within the CNS. The findings indicate an important role of class II immune response products on glial cells during demyelination after virus infection.
Serologic Studies of I-E/I-C Gene Products in Haplotypes H-2b, H-2s, H-2q, and H-2f
David, Chella S., Neely, Brian C.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 121 | Issue: 4 | Pages: 1607-1607

10.4049/jimmunol.121.4.1607.d Get It

Abstract The I-E and I-C subregion products have been identified specifically in haplotypes H-2k and H-2d. Haplotypes H-2p and H-2r are assumed to express products of I-E/I-C subregion on the basis of cross-reactions with anti-I-Ek sera. Anti-I-Ek or I-Ed sera do not cross-react with haplotypes H-2s, H-2b, H-2q, and H-2f. Specific immunizations to produce anti-I-Eb and anti-I-Es alloantisera have been unsuccessful. We turned to xenoimmunization to serologically identify the gene products of this chromosomal segment in the above haplotypes. NP-40 detergent solubilized antigenic material mixed in Freund's complete adjuvant were immunized into rabbits. Two weeks later a booster was given and the rabbits bled one week later for antisera analyses. The rabbits were then boosted once a month and bled periodically. The rabbit antiserum reacted with all mouse strains. Absorptions with appropriate recombinants showed the presence of specific antibodies against the I region products. For example, rabbit anti-B10 serum after absorption with B10.A (3R) left residual activity against B10.A (18R), suggesting antigen(s) mapping between I-J and H-2D. The antiserum was further absorbed with B10.F (13R) to make it specific for I-E/IC subregions. Rabbit anti-B10.M sera, after absorption in ATFR.1 reacts with ATFR.5, suggesting activity in the K and I regions. Since absorption with platelets did not remove activity for spleen cells, presence of anti-If antibodies is suggested. Sequential immunoprecipitation analysis will be performed to screen for anti-I-E/I-C antibodies. Rabbit anti-B10.G and Rabbit anti-B10.S sera are currently being analyzed for I region activity.
Extensive polymorphism surrounding the murine Ia A beta chain gene.
Robinson, Randy , Germain, Ronald N. , McKean, D J, Mescher, M F, Seidman, J.G., Seidman, Jonathan G. , Seidman, Jonathan G

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 131 | Issue: 4 | Pages: 2025-2031

10.4049/jimmunol.131.4.2025 Get It

Abstract A segment of the murine immune response-associated (Ia) antigen A beta chain mRNA has been cloned, and this cDNA clone has been used to examine the organization of the genes encoding these highly polymorphic cell surface proteins. To isolate this clone, pIA beta-1, we screened 5000 cDNA clones by a filter hybridization-selection assay using a rabbit heteroantiserum to identify the A beta chain produced in in vitro translation reactions. This clone corresponds to a segment of the mRNA encoding the beta chain of the murine I-A antigen. The 464 bp nucleotide sequence of the insert is consistent with a cDNA clone encoding the carboxyl end of the murine A beta chain. Comparison of this nucleotide sequence to a human Ia beta chain-derived cDNA clone suggests that the two clones could encode proteins that are about 90% homologous in this region. Southern blot analysis using pIA beta-1 as a probe to investigate the structure of the A beta chain gene in inbred strains of mice allows two conclusions. First, there is only one A beta chain gene homologous to this cDNA clone in each haploid mouse genome. Second, the restriction fragments encoding this gene are highly polymorphic. We postulate that the mechanism which generates polymorphic variation of the A beta chain may be involved in generating the restriction site polymorphism within or near the A beta chain gene.
Lack of gene complementation prevents expression of I-Ek in recombinant A.TFR5.
McCormick, John F., David, Chella S., Lafuse, William P.

Mayo Clinic

The Journal of Immunology | December 30, 2022 | Volume: 124 | Issue: 5 | Pages: 2511-2513

10.4049/jimmunol.124.5.2511 Get It

Abstract The I-E molecule is produced by complementation of genes in I-A (Ae) and I-E (E alpha). Ia specificities 22 and 23 are generated by the hybrid molecule, whereas Ia.7 is an allotypic determinant presumably on the alpha-chain of the I-E molecule. Recombinant A.TFR5 (AfEk) lacks detectable I-E molecule since Af and Ek cannot complement. In a cross between A.TFR5 and B10.A(4R) (AkEb), Aek and E alpha k can successfully complement to express the I-Ek molecule on the cell surface of the heterozygote. Haplotypes H-2b and H-2s can also provide the permissive Abe and Ase molecules for complementation with Ek alpha of A.TFR5.
Understanding neuronal gene expression changes induced by distal demyelination or inflammatory insult (BA6P.137)
Clarkson, Ben, Mirchia, Kanish , Kim, Hyo , LaFrance‐Corey, Reghann G., Howe, Charles W., Sauer, Brian, Howe, Charles

Mayo Clinic

The Journal of Immunology | December 30, 2022 | Volume: 194 | Issue: 1_Supplement | Pages: 114.18-114.18

10.4049/jimmunol.194.supp.114.18 Get It

Abstract MR imaging suggests an anatomic correspondence between WM and GM lesions in progressing MS patients, suggesting an underlying neuronal-signaling or neurodegenerative element to the progressive disease state. While retrograde signals evolving from stressed axons that alter soma gene expression have been previously described in models of axonal transection or crush injury, those resulting from inflammation and demyelination are unknown. Using microfluidic chambers that segregate neuronal soma and axons, we have previously demonstrated increased axonal MHC I following treatment with IFNg, a cytokine prominent in demyelinating MS lesions. Furthermore, expression of antigen-loaded MHC I predisposed axons to injury by antigen-specific CD8+ T cells in vitro. Here we report that neurons also upregulate expression of MHC class Ib mRNAs in response to axonal stimulation with IFNg. Genes most highly upregulated following cytokine treatment included H2-M3, H2-Q5, H2-Q6, H2-Q7, H2-Q8, H2-T10 , and H2-T23. We further report the development of an in vivo model system for measuring axonal vulnerability to antigen-specific immune attack following demyelination using an AAV vector to induce neuron-specific expression of axonally-targeted neoantigen (ovalbumin) tagged with cleavable eGFP. We also present optimized methods using AAV vectors in mice for infecting retinal, motor cortex, and hippocampal neurons to induce target gene expression in axons projecting to optic nerve and corpus collosum.
Gene‐based polygenic score analysis identifies novel immune genes with deleterious variants that associate with Alzheimer’s disease
Reddy, Joseph S. , Wang, Xue , Allen, Mariet , Carrasquillo, Minerva M. , Gregory, Jenkins D., Ertekin‐Taner, Nilüfer , Younkin, Steven G. , Carrasquillo, Minerva M. , Biernacka, Joanna M. , Coombes, Brandon J.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.066231 Get It

AbstractBackgroundIn the Alzheimer’s disease sequencing project (ADSP) whole exome dataset, only the well‐known TREM2.pR47H variant shows genome‐wide significance by conventional single variant analysis. To identify novel AD genes related to TREM2, we used gene‐based polygenic score analysis (PGSA) to evaluate an immune, temporal cortical co‐expression network with 229 genes including TREM2.MethodThe most recent whole exome variant call files from the ADSP (NG00067.v7) were subjected to stringent quality control. Post‐QC samples were divided into discovery (4174 samples sequenced at Broad), test (3299 samples sequenced at WashU), and follow‐up (2273 samples sequenced at Baylor) sets. The pruned variants (r2 < 0.2) with a minor allele count over 20 in each gene were analyzed by Broad/WashU PGSA thereby obtaining P‐values (gPbr.wa) for each gene in WashU samples. To assess significance in independent Baylor samples, cumulative Broad/Baylor PGSA was performed using a novel approach in which variants were stratified by both gene (gPbr.wa) and variant (Broad.P).ResultAfter excluding TREM2, the five variants with gPbr.wa ≤ 0.08 and Broad.P ≤ 0.03 showed significant association in Broad/Baylor PGSA. One of these variants showed no evidence of association with AD in the combined dataset. Polygenic scores for the other four variants, which were in three genes, showed significant association in Baylor samples, and significant, essentially identical association in WashU samples. Polygenic scores for nine additional variants in these genes (0.03> Broad.P ≤ 0.13) also showed significant, essentially identical association in Baylor and WashU samples. The association of these 13 variants with AD was driven primarily by six deleterious, protein‐altering variants with minor allele frequencies less than 1%, but the other 7 variants also contributed.ConclusionUsing gene‐based polygenic score analysis to analyze an immune co‐expression network, we identify three novel immune genes with actionable nonsynonymous and stopgain variants that show significant, replicable association with AD in the most recent release of the ADSP whole exome dataset.
Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter ( NIS ) Gene Therapy Improves Survival of Glioblastoma-bearing Mice
Kitzberger, Carolin , Spellerberg, Rebekka , Han, Yang , Schmohl, Kathrin A. , Stauss, Christina , Zach, Christian , Kälin, Roland E. , Eiber, Matthias , Schilling, Franz , Glaß, Rainer , Weber, Wolfgang , Wagner, Ernst , Nelson, Peter J. , Spitzweg, Christine , Multhoff, Gabriele , Eiber, Matthias , Schilling, Franz , Glass, Rainer , Weber, Wolfgang A , Wagner, Ernst , Nelson, Peter J , Spitzweg, Christine

Mayo Clinic

Clinical Cancer Research | December 14, 2022 | Volume: 29 | Issue: 5 | Pages: 930-942

10.1158/1078-0432.ccr-22-1433 | PMID 36516189 Get It

Abstract Purpose: Mesenchymal stem cells (MSC) have emerged as cellular-based vehicles for the delivery of therapeutic genes in cancer therapy based on their inherent tumor-homing capability. As theranostic gene, the sodium iodide symporter (NIS) represents a successful target for noninvasive radionuclide-based imaging and therapy. In this study, we applied genetically engineered MSCs for tumor-targeted NIS gene transfer in experimental glioblastoma (GBM)—a tumor with an extremely poor prognosis. Experimental Design: A syngeneic, immunocompetent GL261 GBM mouse model was established by subcutaneous and orthotopic implantation. Furthermore, a subcutaneous xenograft U87 model was used. Bone marrow–derived MSCs were stably transfected with a NIS-expressing plasmid driven by the constitutively active cytomegalovirus promoter (NIS-MSC). After multiple or single intravenous injection of NIS-MSCs, tumoral iodide uptake was monitored in vivo using 123I-scintigraphy or 124I-PET. Following validation of functional NIS expression, a therapy trial with 131I was performed on the basis of the most optimal application regime as seen by 124I-PET imaging in the orthotopic approach. Results: A robust tumoral NIS-specific radionuclide accumulation was observed after NIS-MSC and radioiodide application by NIS-mediated in vivo imaging. NIS immunofluorescence staining of GBM and non-target tissues showed tumor-selective MSC homing along with NIS expression. Application of therapeutically effective 131I led to significantly delayed tumor growth and prolonged median survival after NIS-MSC treatment as compared with controls. Conclusions: A strong tumor-selective recruitment of systemically applied MSCs into GBM was found using NIS as reporter gene followed by successful therapeutic application of radioiodide demonstrating the potential use of NIS-based MSCs as therapy vehicles as a new GBM therapy approach.
Osteoarthritis gene therapy in 2022
Evans, Christopher H. , Ghivizzani, Steven C. , Robbins, Paul D.

Mayo Clinic

Current Opinion in Rheumatology | December 12, 2022 | Volume: 35 | Issue: 1 | Pages: 37-43

10.1097/bor.0000000000000918 | PMID 36508307 Get It

Purpose of review To assess the present status of gene therapy for osteoarthritis (OA). Recent findings An expanding list of cDNAs show therapeutic activity when introduced into the joints of animals with experimental models of OA. In vivo delivery with adenovirus or adeno-associated virus is most commonly used for this purpose. The list of encoded products includes cytokines, cytokine antagonists, enzymes, enzyme inhibitors, growth factors and noncoding RNA. Elements of CRISPR-Cas have also been delivered to mouse knees to ablate key genes. Several human trials have been initiated, using transgenes encoding transforming growth factor-β 1 , interleukin-1 receptor antagonist, interferon-β, the NKX3.2 transcription factor or variant interleukin-10. The first of these, using ex vivo delivery with allogeneic chondrocytes, gained approval in Korea which was subsequently retracted. However, it is undergoing Phase III clinical trials in the United States. The other trials are in Phase I or II. No gene therapy for OA has current marketing approval in any jurisdiction. Summary Extensive preclinical data support the use of intra-articular gene therapy for treating OA. Translation is beginning to accelerate and six gene therapeutics are in clinical trials. Importantly, venture capital has begun to flow and at least seven companies are developing products. Significant progress in the future can be expected.
Cloned antibodies from patients with HIT provide new clues to HIT pathogenesis
Zhu, Wen , Zheng, Yongwei , Yu, Mei , Wu, Ya‐Ling , Wei, Jianhui, Fu, Guoping, Schneider, Nicholas O. , Jones, Curtis G., Irani, Mehraboon S. , Padmanabhan, Anand , Aster, Richard H. , Wang, Demin , Wen, Renren , Zhou, Lu , Schneider, Nicholas , Padmanabhan, Anand , Wang, Demin , Wen, Renren , Yu, Mei, Wu, Yaling, Lü, Zhou , Zhou, Lu

Mayo Clinic

Blood | December 9, 2022 | Volume: 141 | Issue: 9 | Pages: 1060-1069

10.1182/blood.2022017612 | PMID 36493339 Get It

AbstractHeparin-induced thrombocytopenia (HIT) is a serious adverse drug reaction characterized by antibodies that recognize platelet factor 4/heparin complexes (PF4/H) and activate platelets to create a prothrombotic state. Although a high percentage of heparin-treated patients produce antibodies to PF4/H, only a subset also makes antibodies that are platelet activating (PA). A close correlation between PA antibodies and the likelihood of experiencing HIT has been demonstrated in clinical studies, but how PA (presumptively pathogenic) and nonactivating (NA) (presumptively benign) antibodies differ from each other at the molecular level is unknown. To address this issue, we cloned 7 PA and 47 NA PF4/H-binding antibodies from 6 patients with HIT and characterized their structural and functional properties. Findings showed that PA clones differed significantly from NA clones in possessing 1 of 2 heavy chain complementarity-determining region 3 (HCDR3) motifs, RX1-2R/KX1-2R/H (RKH) and YYYYY (Y5), in an unusually long complementarity-determining region 3 (≥20 residues). Mutagenic studies showed that modification of either motif in PA clones reduced or abolished their PA activity and that appropriate amino acid substitutions in HCDR3 of NA clones can cause them to become PA. Repertoire sequencing showed that the frequency of peripheral blood IgG+ B cells possessing RKH or Y5 was significantly higher in patients with HIT than in patients without HIT given heparin, indicating expansion of B cells possessing RKH or Y5 in HIT. These findings imply that antibodies possessing RKH or Y5 are relevant to HIT pathogenesis and suggest new approaches to diagnosis and treatment of this condition.